Compare · HIMS vs REUN
HIMS vs REUN
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and Reunion Neuroscience Inc. (REUN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and REUN operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS carries a market cap of $7.41B.
- HIMS has hit the wire 24 times in the past 4 weeks while REUN has been quiet.
- HIMS has more recent analyst coverage (25 ratings vs 0 for REUN).
- Company
- Hims & Hers Health Inc.
- Reunion Neuroscience Inc.
- Price
- $31.75+2.16%
- $1.13+1.80%
- Market cap
- $7.41B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 24
- 0
- Recent ratings
- 25
- 0
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
Latest HIMS
- Chief Policy Officer Autor Deborah M. sold $467,128 worth of shares (16,773 units at $27.85) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 48,961 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi sold $148,111 worth of shares (4,938 units at $29.99) as part of a pre-agreed trading plan and exercised 4,938 shares at a strike of $5.01 (SEC Form 4)
- Chief Legal Officer Boughton Soleil sold $691,808 worth of shares (25,111 units at $27.55) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 313,964 units (SEC Form 4)
- Chief Legal Officer Boughton Soleil converted options into 42,261 shares and covered exercise/tax liability with 21,500 shares, increasing direct ownership by 7% to 339,075 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Carroll Patrick Harrison converted options into 26,187 shares and covered exercise/tax liability with 10,201 shares, increasing direct ownership by 9% to 197,847 units (SEC Form 4) (for tax liability)
- Director Schultz Kare converted options into 6,623 shares, increasing direct ownership by 34% to 26,020 units (SEC Form 4)
- Chief Policy Officer Autor Deborah M. converted options into 32,920 shares and covered exercise/tax liability with 16,147 shares, increasing direct ownership by 34% to 65,734 units (SEC Form 4) to satisfy withholding tax
- CTO Elshenawy Mohamed converted options into 188,285 shares and covered exercise/tax liability with 95,798 shares, increasing direct ownership by 92% to 193,510 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Chi Michael converted options into 86,265 shares and covered exercise/tax liability with 47,702 shares, increasing direct ownership by 9% to 470,687 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Dudum Andrew converted options into 154,993 shares and covered exercise/tax liability with 78,859 shares, increasing direct ownership by 8% to 1,033,177 units (SEC Form 4) to satisfy withholding obligation
Latest REUN
- SEC Form 15-12G filed by Reunion Neuroscience Inc.
- Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
- Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
- SEC Form 6-K filed by Reunion Neuroscience Inc.
- SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)
- SEC Form F-10POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form S-8 POS filed by Reunion Neuroscience Inc.
- SEC Form 25-NSE filed by Reunion Neuroscience Inc.
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement